Paternité, pas d'utilisation commerciale, partage des conditions initiales à l'identique
Langue
English
Extrait
The legally binding text is the original French version TRANSPARENCY COMMITTEE
OPINION 14 March 2007 CYMBALTA 30 mg, gastroresistant capsule Polyvinylchloride (PVC), polyethylene (PE) and polychlorotrifluoroethylene (PCTFE) blister pack(s) sealed with an aluminium foil, containing 7 capsules (CIP 370 237-5) and 28 capsules (CIP 365 864-5) CYMBALTA 60 mg, gastroresistant capsule Polyvinylchloride (PVC), polyethylene (PE) and polychlorotrifluoroethylene (PCTFE) blister pack(s) sealed with an aluminium foil, containing 28 capsules (CIP 365 865-1) Polyvinylchloride (PVC), polyethylene (PE) and polychlorotrifluoroethylene (PCTFE) blister pack(s) sealed with an aluminium foil, containing 100 capsules (CIP 570 777-3) Applicant : LILLY Duloxetine List I Date of the Marketing Authorisations (centralised procedure): Treatment of major depressive episodes (i.e. characteristic symptoms) - 17 December 2004 Treatment of diabetic peripheral neuropathic pain in adults - 4 July 2005 Reason for request: Inclusion of CYMBALTA 30 mg (B/7, B/28) and CYMBALTA 60 mg (B/28 and B/100) on the list of medicines approved for use by hospitals Inclusionof CYMBALTA 30 mg (B/7 and B/28) and CYMBALTA 60 mg (B/28) on the list of medicines reimbursed by National Insurance Health Technology Assessment Division